This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Jan;120(1):170-1.

doi: 10.1046/j.1365-2141.2003.03983_5.x.

t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients

Jerry M Winkler, Philip Greipp, Rafael Fonseca

PMID: 12492597
DOI: 10.1046/j.1365-2141.2003.03983_5.x

Comment

t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients

Jerry M Winkler et al. Br J Haematol. 2003 Jan.

. 2003 Jan;120(1):170-1.

doi: 10.1046/j.1365-2141.2003.03983_5.x.

Authors

Jerry M Winkler, Philip Greipp, Rafael Fonseca

PMID: 12492597
DOI: 10.1046/j.1365-2141.2003.03983_5.x

No abstract available

PubMed Disclaimer

Comment in

FGFR3 dysregulation and clinical outcome in myeloma.
Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE. Rasmussen T, et al. Br J Haematol. 2003 Jan;120(1):166. doi: 10.1046/j.1365-2141.2003.03983_1.x. Br J Haematol. 2003. PMID: 12492593 No abstract available.

Comment on

FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance.
Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE. Rasmussen T, et al. Br J Haematol. 2002 Jun;117(3):626-8. doi: 10.1046/j.1365-2141.2002.03429.x. Br J Haematol. 2002. PMID: 12028033

Similar articles

The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance.
Fonseca R, Oken MM, Greipp PR; Eastern Cooperative Oncology Group Myeloma Group. Fonseca R, et al. Blood. 2001 Aug 15;98(4):1271-2. doi: 10.1182/blood.v98.4.1271. Blood. 2001. PMID: 11510469 No abstract available.
Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation.
Intini D, Fabris S, Storlazzi T, Otsuki T, Ciceri G, Verdelli D, Lombardi L, Rocchi M, Neri A. Intini D, et al. Br J Haematol. 2004 Aug;126(3):437-9. doi: 10.1111/j.1365-2141.2004.05048.x. Br J Haematol. 2004. PMID: 15257719 No abstract available.
FGFR3 dysregulation and clinical outcome in myeloma.
Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE. Rasmussen T, et al. Br J Haematol. 2003 Jan;120(1):166. doi: 10.1046/j.1365-2141.2003.03983_1.x. Br J Haematol. 2003. PMID: 12492593 No abstract available.
Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event.
Geller MD, Pei Y, Spurgeon SE, Durum C, Leeborg NJ. Geller MD, et al. Cancer Genet. 2014 Jul-Aug;207(7-8):340-3. doi: 10.1016/j.cancergen.2014.09.004. Epub 2014 Sep 19. Cancer Genet. 2014. PMID: 25441688 Review.
Spontaneous remission in a patient with t(4;14) translocation multiple myeloma.
Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, Zeng S, Fonseca R, Kukreti V. Puig N, et al. J Clin Oncol. 2009 Nov 20;27(33):e194-7. doi: 10.1200/JCO.2009.22.0392. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805681 Review. No abstract available.

See all similar articles

Cited by

RNASeq Analysis for Accurate Identification of Fusion Partners in Tumor Specific Translocations Detected by Standard FISH Probes in Hematologic Malignancies.
Koduru P, Chen W, Fuda F, Kaur G, Awan F, John S, Garcia R, Gagan J. Koduru P, et al. Clin Pathol. 2024 Feb 16;17:2632010X241230262. doi: 10.1177/2632010X241230262. eCollection 2024 Jan-Dec. Clin Pathol. 2024. PMID: 38371338 Free PMC article.
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, Larratt LM, Mant MJ, Reiman T, Belch AR, Pilarski LM. Keats JJ, et al. Blood. 2005 May 15;105(10):4060-9. doi: 10.1182/blood-2004-09-3704. Epub 2005 Jan 27. Blood. 2005. PMID: 15677557 Free PMC article.
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. Holkova B, et al. Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7. Clin Cancer Res. 2016. PMID: 26446942 Free PMC article. Clinical Trial.
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.
Chu L, Su MY, Maggi LB Jr, Lu L, Mullins C, Crosby S, Huang G, Chng WJ, Vij R, Tomasson MH. Chu L, et al. J Clin Invest. 2012 Aug;122(8):2793-806. doi: 10.1172/JCI63051. Epub 2012 Jul 2. J Clin Invest. 2012. PMID: 22751105 Free PMC article.
Genetic events in the pathogenesis of multiple myeloma.
Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Chng WJ, et al. Best Pract Res Clin Haematol. 2007 Dec;20(4):571-96. doi: 10.1016/j.beha.2007.08.004. Best Pract Res Clin Haematol. 2007. PMID: 18070707 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information